drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR T cells)
drug_description
Lentivirally transduced T cells expressing an anti-CD33 chimeric antigen receptor with CD3ζ signaling and 4-1BB costimulation to recognize and kill CD33-positive AML cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Lentivirally transduced T cells engineered to express an anti‑CD33 chimeric antigen receptor with CD3ζ signaling and 4‑1BB costimulation. Upon binding CD33 on AML cells, the CAR activates T‑cell cytotoxicity and cytokine release, leading to targeted lysis of CD33‑positive leukemia cells.
drug_name
CART33
nct_id_drug_ref
NCT05945849